Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel

FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.

Oxycodone is the generic name for a range of opoid pain killing tablets. Prescription bottle for Oxycodone tablets and pills on metal table for opioid epidemic illustration

Mallinckrodt PLC is seeking to replace its immediate release oxycodone tablets with an abuse-deterrent version, MNK-812. But it may have a hard time getting advisory committee backing as the US FDA appears to find that it is no better than non-abuse deterrent IR oxycodone in deterring intranasal abuse.

The agency said it cannot determine its potential to deter intravenous abuse until the company submits final study results.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers